FDA
- Status: approved
🇺🇸 NGENLA (Somatrogon) in United States
2 US adverse-event reports
Marketing authorisation
Safety signals — FAERS
Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.
- Window: 19 April 2025 – 19 April 2026
- Total reports: 2
Most-reported reactions
- Device Breakage — 1 report (50%)
- Hallucination — 1 report (50%)
Pricing & reimbursement
- annual_list: USD 9684.00 per year
NGENLA (Somatrogon) in other countries
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Other Hematology approved in United States
Frequently asked questions
Is NGENLA (Somatrogon) approved in United States?
Yes. FDA has authorised it.
Who is the marketing authorisation holder for NGENLA (Somatrogon) in United States?
Pfizer is the originator. The local marketing authorisation holder may differ — check the official source linked above.
What does NGENLA (Somatrogon) cost in United States?
annual_list: USD 9684.00 per year. Final patient cost depends on reimbursement and any patient access scheme.